Regression of pressure overload-induced left ventricular hypertrophy in mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 288, Issue 6 57-6, 2005, Pages

  Gao, Xiao Ming ^a   Kiriazis, Helen ^a   Moore, Xiao Lei ^a   Feng, Xin Heng ^a   Sheppard, Karen ^b   Dart, Anthony ^a   Du, Xiao Jun ^a,c  

^a ALFRED HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Aortic banding; Cardiac function remodeling; Model

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATINASE A; MYOSIN HEAVY CHAIN ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL SIZE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; GENE EXPRESSION; HEART DILATATION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HISTOLOGY; MALE; MOUSE; MUSCLE CELL; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; REMISSION; SARCOPLASMIC RETICULUM;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CALCIUM-TRANSPORTING ATPASES; COLLAGEN; DISEASE MODELS, ANIMAL; DNA PRIMERS; ECHOCARDIOGRAPHY; FEMALE; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; PRESSURE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 19344364794     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00836.2004     Document Type: Article

References (38)

1. Bocker W, Hupf H, Grimm D, Kurzidim K, and Schunkert H. Effects of indapamide in rats with pressure overload left ventricular hypertrophy. J Cardiovasc Pharmacol 36: 481-486, 2000.
2. Botchway AN, Turner MA, Sheridan DJ, Flores NA, and Fry CH. Electrophysiological effects accompanying regression of left ventricular hypertrophy. Cardiovasc Res 60: 510-517, 2003.
3. Brilla CG. Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc Res 46: 324-331, 2000.
4. Brilla CG, Janicki JS, and Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 69: 107-115, 1991.
5. Brilla CG and Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 26: 671-677, 1992.
6. 2-Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 101: 71-77, 2000.
7. Friddle CJ, Koga T, Rubin EM, and Bristow J. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc Natl Acad Sci USA 97: 6745-6750, 2000.
8. 2-adrenergic receptor overexpression. Endocrinology 144: 4097-4105, 2003.
9. Haider AW, Larson MG, Benjamin EJ, and Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32: 1454-1459, 1998.
10. Hoit BD and Nadeau JH. Phenotype-driven genetic approaches in mice: high-throughput phenotyping for discovering new models of cardiovascular disease. Trends Cardiovasc Med 11: 82-89, 2001.
11. Hunter JJ and Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341: 1276-1283, 1999.
12. Ikonomidis I, Tsoukas A, Parthenakis F, Gournizakis A, Kassimatis A, Rallidis L, and Nihoyannopoulos P. Four year follow-up of aortic valve replacement for isolated aortic stenosis: a link between reduction in pressure overload, regression of left ventricular hypertrophy, and diastolic function. Heart 86: 309-316, 2001.
13. Imamura SI, Takao A, and Matsuoka R. Regression speed of cardiac myosin heavy-chain isozyme V3 in loaded right or left ventricle after relief of the load. Eur J Clin Invest 26: 240-246, 1996.
14. 2+ ATPase modifies the transition from hypertrophy to early heart failure. Circ Res 89: 422-429, 2001.
15. Janicki JS, Brower GL, Gardner JD, Chancey AL, and Stewart JA Jr. The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev 9: 33-42, 2004.
16. Kelm M, Schafer S, Mingers S, Heydthausen M, Vogt M, Motz W, and Strauer BE. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 14: 1357-1364, 1996.
17. Kingsbury M, Mahnke A, Turner M, and Sheridan D. Recovery of coronary function and morphology during regression of left ventricular hypertrophy. Cardiovasc Res 55: 83-96, 2002.
18. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, and Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 60: 560-565, 1987.
19. Levy D, Garrison RJ, Savage DD, Kannel WB, and Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 110: 101-107, 1989.
20. Liao Y, Ishikura F, Beppu S, Asakura M, Takashima S, Asanuma H, Sanada S, Kim J, Ogita H, Kuzuya T, Node K, Kitakaze M, and Hori M. Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. Am J Physiol Heart Circ Physiol 282: H1703-H1708, 2002.
21. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, and Izumo S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109: 3050-3055, 2004.
22. Miyata S, Minobe W, Bristow MR, and Leinwand LA. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 86: 386-390, 2000.
23. Nakamura A, Rokosh DG, Paccanaro M, Yee RR, Simpson PC, Grossman W, and Foster E. LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. Am J Physiol Heart Circ Physiol 281: H1104-H1112, 2001.
24. 2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. FASEB J 17: 61-63, 2003.
25. Ogita H, Node K, Liao Y, Ishikura F, Beppu S, Asanuma H, Sanada S, Takashima S, Minamino T, Hori M, and Kitakaze M. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension 43: 237-242, 2004.
26. Oikarinen L, Nieminen MS, Toivonen L, Viitasalo M, Wachtell K, Papademetriou V, Jern S, Dahlof B, Devereux RB, and Okin PM. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. Am Heart J 145: 919-925, 2003.
27. Panidis IP, Kotler MN, Ren JF, Mintz GS, Ross J, and Kalman P. Development and regression of left ventricular hypertrophy. J Am Coll Cardiol 3: 1309-1320, 1984.
28. Perlini S, Muiesan ML, Cuspidi C, Sampieri L, Trimarco B, Aurigemma GP, Agabiti-Rosei E, and Mancia G. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation 103: 678-683, 2001.
29. Rajappan K, Rimoldi OE, Camici PG, Bellenger NG, Pennell DJ, and Sheridan DJ. Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation 107: 3170-3175, 2003.
30. Rials SJ, Xu X, Wu Y, Liu T, Marinchack RA, and Kowey PR. Restoration of normal ventricular electrophysiology in renovascular hypertensive rabbits after treatment with losartan. J Cardiovasc Pharmacol 37: 317-323, 2001.
31. Saadane N, Alpert L, and Chalifour LE. Expression of immediate early genes, GATA-4. and Nkx-2.5 in adrenergic-induced cardiac hypertrophy and during regression in adult mice. Br J Pharmacol 127: 1165-1176, 1999.
32. Schmieder RE, Martus P, and Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275: 1507-1513, 1996.
33. Sheppard KE, Li KX, and Autelitano DJ. Corticosteroid receptors and 11β-hydroxysteroid dehydrogenase isoforms in rat intestinal epithelia. Am J Physiol Gastrointest Liver Physiol 277: G541-G547, 1999.
34. 2-Adrenergic receptor overexpression driven by α-MHC promoter is downregulated in hypertrophied and failing myocardium. Cardiovasc Res 47: 133-141, 2000.
35. Villari B, Vassalli G, Monrad ES, Chiariello M, Turina M, and Hess OM. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 91: 2353-2358, 1995.
36. Walther T, Schubert A, Falk V, Binner C, Kanev A, Bleiziffer S, Walther C, Doll N, Autschbach R, and Mohr FW. Regression of left ventricular hypertrophy after surgical therapy for aortic stenosis is associated with changes in extracellular matrix gene expression. Circulation 104: 154-158, 2001.
37. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, and Bashey RI. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 62: 757-765, 1988.
38. 11 in cardiomyocytes. Nat Med 7: 1236-1240, 2001.